Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review

The risk of thromboembolic complications associated with the use of combined oral contraceptives (COCs) and hormone replacement therapy is a concern for both physicians and patients. The work aimed to analyze existing data on the use of COCs and their associated thromboembolic risk. This review summ...

Full description

Saved in:
Bibliographic Details
Main Authors: Nina A. Suricova, Anna S. Gluchova, Evgeny E. Kravchenko, Vladislav A. Vishnyakov, Evgeny I. Mokin
Format: Article
Language:English
Published: Concilium Medicum 2025-01-01
Series:КардиоСоматика
Subjects:
Online Access:https://cardiosomatics.ru/2221-7185/article/viewFile/640894/204323
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849737268053409792
author Nina A. Suricova
Anna S. Gluchova
Evgeny E. Kravchenko
Vladislav A. Vishnyakov
Evgeny I. Mokin
author_facet Nina A. Suricova
Anna S. Gluchova
Evgeny E. Kravchenko
Vladislav A. Vishnyakov
Evgeny I. Mokin
author_sort Nina A. Suricova
collection DOAJ
description The risk of thromboembolic complications associated with the use of combined oral contraceptives (COCs) and hormone replacement therapy is a concern for both physicians and patients. The work aimed to analyze existing data on the use of COCs and their associated thromboembolic risk. This review summarizes the findings of Russian and international studies conducted in women using COCs who experienced thrombotic complications. A total of 37 sources were used, including articles indexed in international citation databases such as PubMed (MEDLINE) and Scopus, as well as foundational studies and monographs indexed in the Russian Science Citation Index (RSCI). Data were selected using the following keywords: сердечно-сосудистые заболевания (cardiovascular diseases), комбинированные оральные контрацептивы (combined oral contraceptives), КОК (COCs), тромбоэмболия лёгочной артерии (pulmonary embolism), ТЭЛА (PE), and инфаркт миокарда (myocardial infarction). Materials with unidentified authorship, educational manuals, pseudoscientific online sources, and publications not relevant to the topic were excluded. The review revealed that the use of COCs may influence the risk of developing pulmonary embolism (PE); however, thrombus formation is also affected by additional factors. Some studies suggest that third- and fourth-generation COCs may be associated with a higher risk of PE, although the absolute risk remains relatively low. It is important to emphasize that the decision to initiate COC use and the selection of a specific drug should be made by a physician based on the patient’s individual characteristics, medical history, and risk factors. Notably, discontinuation of COCs does not eliminate the risk of PE entirely, as hereditary predisposition, lifestyle, and comorbid conditions may also contribute.
format Article
id doaj-art-8c538404bc894e8fbfba5db2da248060
institution DOAJ
issn 2221-7185
2658-5707
language English
publishDate 2025-01-01
publisher Concilium Medicum
record_format Article
series КардиоСоматика
spelling doaj-art-8c538404bc894e8fbfba5db2da2480602025-08-20T03:06:58ZengConcilium MedicumКардиоСоматика2221-71852658-57072025-01-0116216817510.17816/CS64089476603Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a reviewNina A. Suricova0https://orcid.org/0000-0001-8833-7043Anna S. Gluchova1https://orcid.org/0000-0001-8220-6739Evgeny E. Kravchenko2https://orcid.org/0009-0000-5178-4755Vladislav A. Vishnyakov3https://orcid.org/0009-0001-9554-7986Evgeny I. Mokin4https://orcid.org/0009-0004-2147-2805Orenburg State Medical UniversityOdont Medical CenterOrenburg State Medical UniversityOrenburg State Medical UniversityOrenburg State Medical UniversityThe risk of thromboembolic complications associated with the use of combined oral contraceptives (COCs) and hormone replacement therapy is a concern for both physicians and patients. The work aimed to analyze existing data on the use of COCs and their associated thromboembolic risk. This review summarizes the findings of Russian and international studies conducted in women using COCs who experienced thrombotic complications. A total of 37 sources were used, including articles indexed in international citation databases such as PubMed (MEDLINE) and Scopus, as well as foundational studies and monographs indexed in the Russian Science Citation Index (RSCI). Data were selected using the following keywords: сердечно-сосудистые заболевания (cardiovascular diseases), комбинированные оральные контрацептивы (combined oral contraceptives), КОК (COCs), тромбоэмболия лёгочной артерии (pulmonary embolism), ТЭЛА (PE), and инфаркт миокарда (myocardial infarction). Materials with unidentified authorship, educational manuals, pseudoscientific online sources, and publications not relevant to the topic were excluded. The review revealed that the use of COCs may influence the risk of developing pulmonary embolism (PE); however, thrombus formation is also affected by additional factors. Some studies suggest that third- and fourth-generation COCs may be associated with a higher risk of PE, although the absolute risk remains relatively low. It is important to emphasize that the decision to initiate COC use and the selection of a specific drug should be made by a physician based on the patient’s individual characteristics, medical history, and risk factors. Notably, discontinuation of COCs does not eliminate the risk of PE entirely, as hereditary predisposition, lifestyle, and comorbid conditions may also contribute.https://cardiosomatics.ru/2221-7185/article/viewFile/640894/204323risk factorscombined oral contraceptivespulmonary embolismcardiovascular diseases
spellingShingle Nina A. Suricova
Anna S. Gluchova
Evgeny E. Kravchenko
Vladislav A. Vishnyakov
Evgeny I. Mokin
Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review
КардиоСоматика
risk factors
combined oral contraceptives
pulmonary embolism
cardiovascular diseases
title Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review
title_full Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review
title_fullStr Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review
title_full_unstemmed Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review
title_short Risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy, and their prevention: a review
title_sort risk of thromboembolic events in women using combined oral contraceptives and hormone replacement therapy and their prevention a review
topic risk factors
combined oral contraceptives
pulmonary embolism
cardiovascular diseases
url https://cardiosomatics.ru/2221-7185/article/viewFile/640894/204323
work_keys_str_mv AT ninaasuricova riskofthromboemboliceventsinwomenusingcombinedoralcontraceptivesandhormonereplacementtherapyandtheirpreventionareview
AT annasgluchova riskofthromboemboliceventsinwomenusingcombinedoralcontraceptivesandhormonereplacementtherapyandtheirpreventionareview
AT evgenyekravchenko riskofthromboemboliceventsinwomenusingcombinedoralcontraceptivesandhormonereplacementtherapyandtheirpreventionareview
AT vladislavavishnyakov riskofthromboemboliceventsinwomenusingcombinedoralcontraceptivesandhormonereplacementtherapyandtheirpreventionareview
AT evgenyimokin riskofthromboemboliceventsinwomenusingcombinedoralcontraceptivesandhormonereplacementtherapyandtheirpreventionareview